CK
Cory Kasimov Evercore ISI Group Latest Price Targets & Analyst Ratings
# | Stock | Price | Price Target |
Upside Downside | Rating | Date | |
---|---|---|---|---|---|---|---|
1 |
1
Cytokinetics
CYTK
$6.25B
| $52.20 | $80 |
53%
upside
| Outperform | 2 days ago |
|
2 |
2
Vir Biotechnology
VIR
$733M
| $5.28 | $12 |
127%
upside
| Outperform | 2 days ago |
|
3 |
3
Immunome
IMNM
$884M
| $10.16 | $18 |
77%
upside
| Outperform | 14 days ago |
|
4 |
4
Summit Therapeutics
SMMT
$19B
| $25.52 | $34 |
33%
upside
| Outperform | 24 days ago |
|
5 |
5
Xenon Pharmaceuticals
XENE
$3.02B
| $39.19 | $55 |
40%
upside
| Outperform | 3 months ago |
|
6 |
6
Moderna
MRNA
$9.75B
| $25.05 | $32 |
28%
upside
| In-Line | 4 months ago |
|
7 |
7
Neurocrine Biosciences
NBIX
$14.3B
| $144.33 | $185 |
28%
upside
| Outperform | 4 months ago |
|
8 |
8
BridgeBio Pharma
BBIO
$10.1B
| $53.05 | $50 |
6%
downside
| Outperform | 8 months ago |
|
9 |
9
Edgewise Therapeutics
EWTX
$1.65B
| $15.70 | $50 |
218%
upside
| Outperform | 8 months ago |
|
10 |
10
BioNTech
BNTX
$26.9B
| $111.69 | $125 |
12%
upside
| Outperform | 9 months ago |
|
11 |
11
BioMarin Pharmaceuticals
BMRN
$11B
| $57.51 | $105 |
83%
upside
| Outperform | 10 months ago |
|
12 |
12
Regeneron Pharmaceuticals
REGN
$60.3B
| $568.59 | $1,175 |
107%
upside
| Outperform | 10 months ago |
|
13 |
13
Arcellx
ACLX
$4.01B
| $72.27 | $85 |
18%
upside
| Outperform | 1 year ago |
|
14 |
14
Ultragenyx Pharmaceutical
RARE
$3.06B
| $31.77 | $88 |
177%
upside
| Overweight | 1 year ago |
|
15 |
15
Biogen
BIIB
$20.8B
| $141.90 | $276 |
95%
upside
| Neutral | 3 years ago |
|
16 |
16
Sana Biotechnology
SANA
$746M
| $2.94 | $35 |
1,090%
upside
| Neutral | 4 years ago |
|
17 |
17
Amgen
AMGN
$152B
| $282.13 | $232 |
18%
downside
| Neutral | 5 years ago |
|
18 |
18
Moderna
MRNA
$9.75B
| $25.05 | $89 |
255%
upside
| Neutral | 5 years ago |
|
19 |
19
Regeneron Pharmaceuticals
REGN
$60.3B
| $568.59 | $429 |
25%
downside
| Neutral | 5 years ago |
|
20 |
20
BioNTech
BNTX
$26.9B
| $111.69 | $33 |
70%
downside
| Neutral | 5 years ago |
|
21 |
21
Alkermes
ALKS
$4.95B
| $29.96 | $21 |
30%
downside
| Neutral | 5 years ago |
|